SWOT Analysis for Maze Therapeutics Inc.

Positive Breakout Third Resistance ( LTP > R3)
Relative Outperformance versus Industry over 1 Month
Rising Net Cash Flow and Cash from Operating activity
Relative Outperformance versus Industry over the Quarter (3 Months)
Stocks whose current price is 20% higher than week low, and more than previous close
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
New 52 week high today
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Overbought by Money Flow Index (MFI)
Positive Breakout (LTP > R2)
Positive breakout third resistance ( LTP > R3)
Stock gained more than 20% in one month
Positive Breakout (LTP > R1)
High Volume, High Gain
Top Gainers
Stock with Low PE (PE < = 10)
RSI indicating price strength
Stocks near 52 Week High with Significant Volumes
Volume Shockers
High Volume, High Gain
Highest Recovery from 52 Week Low
Stocks Outperforming their Industry Price Change in the Quarter

Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Degrowth in Quarterly Revenue and Profit in Recent Results(YoY)
Declining profits every quarter for the past 4 quarters